Vanda’s Fanapt Approval Is FDA U-Turn

FDA’s “not approvable” letter for the atypical antipsychotic –only 10 months ago – requested comparative trials against Risperdal and Zyprexa. But approval came without that, although labeling sets up a difficult marketing task.